![]() |
市場調查報告書
商品編碼
2177867
基於胜肽的皮膚緊緻產品市場預測至2034年-按產品類型、產品形態、應用、分銷管道、最終用戶、皮膚類型和地區分類的全球分析Peptide-Based Skin Firming Products Market Forecasts to 2034 - Global Analysis By Product Type, Product Form, Application, Distribution Channel, End User, Skin Type, and By Geography |
||||||
根據 Stratistics MRC 預測,全球肽類緊膚產品市場預計到 2026 年將達到 28 億美元,並在預測期內以 7.2% 的複合年成長率成長,到 2034 年將達到 49 億美元。
肽類緊緻護膚產品是一種外用配方,利用短鏈氨基酸來支持皮膚的結構蛋白,從而增強皮膚的緊緻度和彈性。這些產品含有訊號肽,可刺激膠原蛋白合成;銅肽,可促進皮膚修復;以及膠原蛋白支撐肽,可強化皮膚基質。這些配方有精華液、乳霜、乳液、凝膠和面膜等多種形式,可每天使用,有效改善細紋、皮膚鬆弛和膚質不均等問題,適用於所有膚質,包括乾性、油性和混合性皮膚。
對非侵入性皮膚緊緻療法的需求日益成長
隨著消費者越來越傾向於選擇非侵入性的注射式緊膚療法,市場對無需手術即可獲得明顯提拉效果的胜肽外用製劑的需求日益成長。那些對注射猶豫不決或希望延長診所治療效果的消費者,正在尋找能夠促進膠原蛋白和提升肌膚彈性的日常精華液和乳霜。各大品牌也紛紛推出含有經臨床驗證的高濃度胜肽複合物的產品,不僅提升了產品的可信度,也使其能夠在專業零售通路和美容院線中獲得更高的定價。
成分穩定性和滲透性的局限性
肽類物質在製劑中易受水解、pH值變化和酵素分解的影響,難以保證其穩定性,導致保存期限較短。此外,較大的胜肽分子難以滲透至角質層,難以達到可測量的緊緻效果,這引起了皮膚科醫師的質疑。製造商需要投資包封和遞送系統來保護活性成分,這增加了製劑成本。這些技術限制減緩了創新步伐,限制了濃度方面的宣傳,並將高階定位限制在擁有先進研發能力的供應商手中。
專業通路的拓展
皮膚科診所、醫療美容中心和美容診所將肽類緊緻產品視為將診所治療延伸至居家護理的可靠途徑。接受過能量療法或微針治療的患者通常樂於接受居家緊緻精華液來維持治療效果,這使得居家緊緻精華液的轉換率高於僅透過零售通路銷售。將居家護理套裝作為治療套餐的一部分進行銷售,可以提高診所收入和患者留存率,而專家推薦則支持產品功效,並為醫療保健和零售管道的溢價定價提供了依據。
類視色素A和抗氧化劑作為替代品
類視色素、維生素C和菸鹼醯胺因其緊緻肌膚和改善膚質的功效而廣為人知,而且由於價格低廉並經過臨床驗證,消費者不太願意為僅含胜肽的產品支付更高的價格。許多消費者認為,已有的活性成分足以滿足他們的抗衰老需求。如果知名品牌以相近的價格在其現有的類視色素產品線中添加胜肽混合物,那麼僅含胜肽的產品可能難以脫穎而出。因此,品牌必須透過對比測試來證明其產品在改善肌膚彈性和細紋方面具有可衡量的效果,才能保住貨架空間和價格優勢。
疫情擾亂了專業美容管道,延緩了臨床檢驗工作,限制了胜肽類緊膚產品透過診所合作零售管道的早期推廣。疫情期間,消費者轉向居家抗衰老護理,並在網路上搜尋胜肽類成分,推動了電商通路的嘗試。疫情過後,隨著治療數量的恢復和診所零售項目的拓展,市場需求回升。同時,各大品牌加強了概念驗證,並推出了更穩定的胜肽配方,以滿足消費者對其功效宣稱的嚴格檢驗。
在預測期內,「訊號肽產品」細分市場預計將佔據最大的市場佔有率。
由於訊號肽具有直接促進膠原蛋白合成的作用機制,且在緊緻精華液和乳霜中佔據主導地位,預計在預測期內,訊號肽產品將佔據最大的市場佔有率。配方研發人員青睞訊號肽,是因為它們兼具清晰的技術定位和廣泛的乳液體系相容性。皮膚科醫生在專業領域認可這些胜肽,這有助於提升消費者的信任度和復購率。隨著消費者對緊緻產品需求的不斷成長,含訊號肽的產品仍然是該品類的中流砥柱,並保持著領先的銷售佔有率。
預計在預測期內,「血清」細分市場將呈現最高的複合年成長率。
在預測期內,精華液細分市場預計將呈現最高的成長率,這主要得益於消費者對輕盈、易吸收且能在保濕霜下輸送高濃度胜肽成分的產品偏好。精華液便於在多步驟護膚流程中疊加使用,也使品牌能夠以更高的價格突出肽類成分的濃度和輸送技術。隨著配方研發人員不斷提升肽類成分在水性體系中的穩定性,預計專賣店和品牌自有電商平台上的新款精華液產品將迎來爆發式成長,使其成為成長最快的產品類型。
在預測期內,北美預計將佔據最大的市場佔有率,這主要得益於其高昂的抗衰老支出、完善的皮膚科醫療體係以及消費者對肽類成分的熟悉程度。美國正引領區域銷售成長,這得益於專業零售商和品牌對臨床驗證和專業教育的投入。此外,對以科學為導向的護膚新創公司的積極創業融資以及D2C(直接面對消費者)模式的快速普及,進一步鞏固了該地區在肽類緊膚產品領域的領先地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於該地區人口快速老化、可支配收入不斷成長,以及韓國、中國、日本和印度等國家對預防性緊膚護理的濃厚興趣。消費者正積極採用胜肽類精華液和乳霜,而本土品牌和契約製造也不斷提升其配方研發能力。電子商務的日益普及和皮膚科教育計畫的加強進一步推動了胜肽類緊膚產品的市場普及,使亞太地區成為胜肽類緊膚產品成長最快的區域市場。
According to Stratistics MRC, the Global Peptide-Based Skin Firming Products Market is accounted for $2.8 billion in 2026 and is expected to reach $4.9 billion by 2034 growing at a CAGR of 7.2% during the forecast period. Peptide-based skin firming products are topical formulations that use short chains of amino acids to support the skin's structural proteins and improve the appearance of firmness and elasticity. They contain signal peptides that stimulate collagen synthesis, copper peptides that support repair processes, and collagen-support peptides that reinforce the skin matrix. These formulations are delivered as serums, creams, lotions, gels, and masks, and are applied daily to address fine lines, loss of bounce, and uneven texture across dry, oily, and combination skin types.
Rising Demand for Non-Invasive Firming
Growing consumer preference for non-invasive alternatives to injectable firming treatments is driving demand for peptide-based topical formulations that promise visible lift without clinical procedures. Consumers who are hesitant about needles or who wish to extend the results of in-clinic treatments seek daily-use serums and creams that support collagen and elasticity. Brands respond with high-concentration peptide complexes supported by clinical testing, which strengthens credibility and supports premium pricing across specialty retail and professional channels.
Ingredient Stability and Penetration Limits
Peptides are susceptible to hydrolysis, pH-driven degradation, and enzymatic breakdown within formulations, which complicates stability and shortens shelf life. Large peptide molecules also face limited penetration through the stratum corneum, which constrains measurable firming outcomes and invites skepticism from dermatologists. Manufacturers must invest in encapsulation and delivery systems to protect actives, raising formulation costs. These technical constraints slow innovation, restrict concentration claims, and confine premium positioning to suppliers with advanced development capability.
Professional Channel Expansion
Dermatology clinics, medical spas, and aesthetic practices offer a credible pathway for peptide firming brands to extend in-clinic treatments into home-care regimens. Patients who receive energy-based or microneedling procedures are receptive to take-home firming serums that maintain results, which delivers higher conversion than pure retail launches. Bundling home-care kits with procedure packages improves clinic revenue and patient adherence, while professional endorsement strengthens claims and supports premium pricing across institutional and retail channels.
Substitution by Retinoids and Antioxidants
Retinoids, vitamin C, and niacinamide remain well-understood, inexpensive, and clinically validated for firmness and texture, which reduces willingness to pay premiums for peptide-specific positioning. Many consumers perceive established actives as sufficient for anti-ageing needs. If mainstream brands add peptide blends to existing retinoid lines at comparable prices, dedicated peptide products may struggle to differentiate. Consequently, brands must substantiate measurable elasticity and fine line benefits through comparative trials to defend shelf space and pricing.
The pandemic disrupted professional aesthetic channels and delayed clinical validation work, limiting early peptide firming adoption through clinic-linked retail. During the crisis, consumers shifted toward at-home anti-ageing regimens and researched peptide ingredients online, supporting e-commerce trial. Post-pandemic, returning procedure volumes and expanded clinic retail programs have revived demand, while brands strengthened substantiation and introduced stabilized peptide formats to address scrutiny of efficacy claims.
The Signal Peptide Products segment is expected to be the largest during the forecast period
The Signal Peptide Products segment is expected to account for the largest market share during the forecast period, due to their direct mechanism of supporting collagen synthesis and their established presence across firming serums and creams. Formulators favor signal peptides because they combine clear technical positioning with broad compatibility in emulsion systems. Dermatologists recognize these peptides from professional contexts, which supports consumer trust and repeat purchase. As firming demand grows, signal peptide formulations remain the category anchor, thereby sustaining leading revenue share.
The Serums segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Serums segment is predicted to witness the highest growth rate, driven by consumer preference for lightweight, fast-absorbing formats that deliver concentrated peptides beneath moisturizers. Serums support layering within multi-step routines and allow brands to highlight peptide concentration and delivery technology at premium price points. As formulators improve peptide stability in aqueous systems, serum launches multiply across specialty retail and brand-owned e-commerce, making this the fastest-growing product form segment.
During the forecast period, the North America region is expected to hold the largest market share, due to high anti-ageing spending, mature dermatology infrastructure, and strong consumer familiarity with peptide ingredients. The United States dominates regional revenue, supported by specialty retailers and brands investing in clinical substantiation and professional education. Active venture funding for science-led skincare startups and rapid direct-to-consumer adoption further reinforce the region's leading position in peptide-based skin firming products.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapidly ageing populations, rising disposable incomes, and strong interest in preventive firming routines across South Korea, China, Japan, and India. Consumers readily adopt peptide serums and creams, while local brands and contract manufacturers expand formulation capability. Growing e-commerce availability and dermatology education programs further support adoption, making Asia Pacific the fastest-growing regional market for peptide-based firming products.
Key players in the market
Some of the key players in Peptide-Based Skin Firming Products Market include L'Oreal S.A., The Estee Lauder Companies Inc., Beiersdorf AG, Shiseido Company, Limited, Unilever PLC, The Procter & Gamble Company, Kao Corporation, Kenvue Inc., Amorepacific Corporation, LG H&H Co., Ltd., Coty Inc., Natura &Co, Edgewell Personal Care Company, Galderma Group AG, Pierre Fabre Laboratories, and Rohto Pharmaceutical Co., Ltd.
In October 2026, L'Oreal S.A. launched a signal peptide firming serum with encapsulated delivery technology, supported by elasticity clinical testing and distributed through specialty retailers and brand-owned e-commerce across European and North American markets.
In September 2026, Galderma Group AG expanded its professional skincare portfolio with copper peptide firming creams designed for post-procedure care, targeting dermatology clinics and medical spas with structured education programs across European markets.
In August 2026, Amorepacific Corporation introduced collagen-support peptide masks and gels positioned for visible firmness and skin texture, distributed through specialty retailers and online marketplaces across South Korea and Southeast Asia.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.